6.28
-0.21(-3.24%)
Currency In USD
| Previous Close | 6.49 |
| Open | 6.61 |
| Day High | 6.73 |
| Day Low | 6.27 |
| 52-Week High | 37.5 |
| 52-Week Low | 3.81 |
| Volume | 13,878 |
| Average Volume | 28,210 |
| Market Cap | 10.33M |
| PE | -0.22 |
| EPS | -28.99 |
| Moving Average 50 Days | 6.93 |
| Moving Average 200 Days | 8.18 |
| Change | -0.21 |
If you invested $1000 in Lyra Therapeutics, Inc. (LYRA) since IPO date, it would be worth $6.77 as of October 24, 2025 at a share price of $6.28. Whereas If you bought $1000 worth of Lyra Therapeutics, Inc. (LYRA) shares 3 years ago, it would be worth $26.5 as of October 24, 2025 at a share price of $6.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement WarrantsWATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
GlobeNewswire Inc.
Jun 02, 2025 11:00 AM GMT
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN 2 trial also showed statistically significant improve